Enanta Pharmaceuticals to Participate in Upcoming September Conferences
September 03 2020 - 7:01AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage
biotechnology company dedicated to creating small molecule drugs
for viral infections and liver diseases, today announced that Jay
R. Luly, Ph.D., President and Chief Executive Officer, will
participate in three upcoming virtual conferences in September:
- Baird 2020 Global Healthcare Conference, Fireside Chat at 9:40
a.m. ET on September 10, 2020
- H.C. Wainwright 22nd Annual Global Investment Conference,
Presentation at 1:00 p.m. ET on September 15, 2020
- Oppenheimer Fall Healthcare Life Sciences & MedTech Summit,
Presentation at 3:20 p.m. ET on September 22, 2020
A live webcast of each of the above presentations will be
accessible by visiting the “Events and Presentations” section on
the “Investors” page of Enanta’s website at www.enanta.com. Replays
of the webcasts will be available following the presentations and
will be archived for at least 30 days.
About Enanta
Enanta is using its robust, chemistry-driven approach and drug
discovery capabilities to become a leader in the discovery and
development of small molecule drugs for the treatment of viral
infections and liver diseases. Enanta’s research and development
efforts have produced clinical candidates for the following disease
targets: respiratory syncytial virus (RSV), non-alcoholic
steatohepatitis (NASH) and hepatitis B virus (HBV). Enanta is also
conducting research in human metapneumovirus (hMPV) and SARS-CoV-2
(COVID-19).
Enanta’s research and development activities are funded by
royalties from hepatitis C virus (HCV) products developed under its
collaboration with AbbVie. Glecaprevir, a protease inhibitor
discovered by Enanta, is sold by AbbVie in numerous countries as
part of its leading treatment for chronic HCV infection under the
tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.)
(glecaprevir/pibrentasvir). Please visit www.enanta.com for more
information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200903005245/en/
Investor Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2023 to Apr 2024